As illustrated in Table 3, CAR-NK cell therapies for solid tumors predominantly target malignancies including colorectal cancer, breast cancer, and prostate cancer, with key molecular targets encompassing CLDN6, Anti-5T4, antimesothelin, ROBO1, PSMA, NKG2D ligands, and HER2. Here, FOLH1 is linked to Familial prostate cancer.